» Articles » PMID: 33220304

Fibrillation of Human Calcitonin and Its Analogs: Effects of Phosphorylation and Disulfide Reduction

Overview
Journal Biophys J
Publisher Cell Press
Specialty Biophysics
Date 2020 Nov 21
PMID 33220304
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Some therapeutic peptides self-assemble in solution to form ordered, insoluble, β-sheet-rich amyloid fibrils. This physical instability can result in reduced potency, cause immunogenic side effects, and limit options for formulation. Understanding the mechanisms of fibrillation is key to developing rational mitigation strategies. Here, amide hydrogen-deuterium exchange with mass spectrometric analysis (HDX-MS) coupled with proteolytic digestion was used to identify the early stage interactions leading to fibrillation of human calcitonin (hCT), a peptide hormone important in calcium metabolism. hCT fibrillation kinetics was sigmoidal, with lag, growth, and plateau phases as shown by thioflavin T and turbidity measurements. HDX-MS of fibrillating hCT (pH 7.4; 25°C) suggested early involvement of the N-terminal (1-11) and central (12-19) fragments in interactions during the lag phase, whereas C-terminal fragments (20-32 and 26-32) showed limited involvement during this period. The residue-level information was used to develop phosphorylated hCT analogs that showed modified fibrillation that depended on phosphorylation site. Phosphorylation in the central region resulted in complete inhibition of fibrillation for the phospho-Thr-13 hCT analog, whereas phosphorylation in the N-terminal and C-terminal regions inhibited but did not prevent fibrillation. Reduction of the Cys1-Cys7 disulfide bond resulted in faster fibrillation with involvement of different hCT residues as indicated by pulsed HDX-MS. Together, the results demonstrate that small structural changes have significant effects on hCT fibrillation and that understanding these effects can inform the rational development of fibrillation-resistant hCT analogs.

Citing Articles

Calcitonin treatment for osteoarthritis and rheumatoid arthritis - a systematic review and meta-analysis of preclinical data.

Meyer Gunderoth M, Bannach-Brown A, Winkler T, Keller J, Zahn R, Maleitzke T EFORT Open Rev. 2024; 9(7):600-614.

PMID: 38949173 PMC: 11297409. DOI: 10.1530/EOR-23-0133.


Molecular Insights into the Effects of F16L and F19L Substitutions on the Conformation and Aggregation Dynamics of Human Calcitonin.

Huang F, Huang J, Yan J, Liu Y, Lian J, Sun Q J Chem Inf Model. 2024; 64(11):4500-4510.

PMID: 38745385 PMC: 11349047. DOI: 10.1021/acs.jcim.4c00553.


Deciphering the influence of Y12L and N17H substitutions on the conformation and oligomerization of human calcitonin.

Yan J, Wang Y, Fan X, Zou Y, Ding F, Huang F Soft Matter. 2024; 20(3):693-703.

PMID: 38164981 PMC: 10845004. DOI: 10.1039/d3sm01332d.


Investigating the inhibitory property of DM hCT on hCT fibrillization via its relevant peptide fragments.

Chuang Y, Chang Y, Tu L Protein Sci. 2023; 32(8):e4711.

PMID: 37354016 PMC: 10360389. DOI: 10.1002/pro.4711.


Structural Perturbation of Monomers Determines the Amyloid Aggregation Propensity of Calcitonin Variants.

Liu Y, Wang Y, Zhang Y, Zou Y, Wei G, Ding F J Chem Inf Model. 2022; 63(1):308-320.

PMID: 36456917 PMC: 9839651. DOI: 10.1021/acs.jcim.2c01202.


References
1.
Chen Y, Hu K, Huang B, Lai C, Tu L . Inhibiting Human Calcitonin Fibril Formation with Its Most Relevant Aggregation-Resistant Analog. J Phys Chem B. 2019; 123(48):10171-10180. DOI: 10.1021/acs.jpcb.9b08514. View

2.
Andreotti G, Vitale R, Avidan-Shpalter C, Amodeo P, Gazit E, Motta A . Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue. J Biol Chem. 2010; 286(4):2707-18. PMC: 3024767. DOI: 10.1074/jbc.M110.182014. View

3.
Malmos K, Blancas-Mejia L, Weber B, Buchner J, Ramirez-Alvarado M, Naiki H . ThT 101: a primer on the use of thioflavin T to investigate amyloid formation. Amyloid. 2017; 24(1):1-16. DOI: 10.1080/13506129.2017.1304905. View

4.
Stroop S, Nakamuta H, Kuestner R, Moore E, Epand R . Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions. Endocrinology. 1996; 137(11):4752-6. DOI: 10.1210/endo.137.11.8895343. View

5.
Kammari R, Topp E . Solid-State Hydrogen-Deuterium Exchange Mass Spectrometry (ssHDX-MS) of Lyophilized Poly-d,l-Alanine. Mol Pharm. 2019; 16(7):2935-2946. DOI: 10.1021/acs.molpharmaceut.9b00162. View